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Summary
Equilibrium binding studies on canine mononuclear and granulocytic cells allowthe identification
of a single high affinity receptor for the human C-C chemokine RANTES (dissociation constant,
14 ± 8 pM), that, in contrast to the human RANTES receptor, has no affinity for human
macrophage inflammatory protein lcx (hMIP-lot). A single intradermal injection of hRANTES
in dog resulted in eosinophil- and macrophage-rich inflammatory sites within 4 h. Cell infiltration
peaked at 16-24 h after hRANTES injection. There was histological evidence of intravascular
activation ofeosinophils at 4 h, although eosinophils in the vasculature and interstitium contained
apparently intact granules. Monocytes were the predominant cells adherent to venular endothelium
at 16-24 h. Human MIP-1a elicited no response in canine dermis, whereas monoryte chemo-
attractantprotein 1 caused mild perivascular cuffing with monocytes. In contrast, humaninterleukin
8 induced a neutrophilic dermal infiltrate that was maximal by 4 h after challenge. This provides
the first direct evidence in vivo that RANTES has significant proinflammatory activity and, in
addition, could be a mediator in atopic pathologies characterized by eosinophilic and monocytic
inflammatory responses.
T
he eosinophil is recruited to inflammatory sites of early-
and late-phase immediate hypersensitivity (1, 2), plays
a significant role in the response to parasitic pathogens (3),
is a major cellular component of the inflammatory response,
and is implicated in mucosal damage in bronchial asthma (4).
The mechanism(s) underlying eosinophil recruitment to
inflammatory sites have yet to be completely defined. The
first of these entails increased production and mobilization
of eosinophils from bone marrow by a variety of factors in-
cluding IL-3 and IL-5 (5, 6). Subsequently, there is intravas-
cular priming of eosinophils followed by endothelial adhe-
sion and transmigration mediated by the leukocyte-specific
CD18 integrins and particularly by the very late antigen
4/vascular cell adhesion molecule 1 counter-receptor pair (7,
8), and stimulation of eosinophil chemotaxis and activation
of secretion.
A broad range of chemically diverse chemotaxins have been
described with shared activities on eosinophils and other leu-
kocytes. C5a, platelet-activating factor, and leukotriene B4
(LTB4) are chemotactic for eosinophils and neutrophils, (1) .
RANTES, macrophage inflammatory protein lu (MIP-1cx),
monocyte chemoattractant protein 1 (MCP-1), and IL-8 are
members of the intercrine (9) or chemokine (10, 11) family
of proinflammatory basic chemoattractant polypeptides.
RANTES, MIP-lot, and MCP-1 were defined initially as genes
or proteins expressed in activated leukocytes or as small platelet-
derived growth factor-inducible genes, and are structural
members of the C-C branch of the chemokine family (11),
based on the adjacent position of the first two of a highly
conserved four-cysteine motif (9), whereas IL-8 was defined
as a monoryte-derived neutrophil chemoattractant and is the
paradigm of the C-X-C branch of the chemokines. Only
RANTES and MIP-1cx are chemoattractants in vitro for eo-
sinophils (12, 13), monocytes, and certain T lymphocyte
subsets (14, 15). They have also been described to have vari-
able effects on the activation of eosinophils and the stimula-
tion of secretion in the presence of cytochalasin (13).
The contribution of C-C chemokines to inflammatory
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and by a failure to characterize and correlate in vivo activity
with receptor-ligand specificities andactivities across species.
Nevertheless, a varietyof proinflammatory effects have been
demonstrated by theinjection ofMCP-1 or MIP-1a in vivo
(16, 17). These include recruitment of either neutrophils or
mononuclear cells, dependingupon the specific cytokine. It
has been suggested, without causal evidence, that thesemol-
ecules play an important role in inflammatory recruitment
leading to cell activation and directional migrationof specific
leukocyte subsets and contribute to activation of integrin-
mediated adhesive events necessary for transendothelial migra-
tion (18). Accordingly, we sought to characterize thecanine
receptors for human C-C chemokines and directly evaluated
human C-C chemokine activities in vivo by comparing the
capability of human (h)RANTES, hMCP-11, hMIP-17a,
and hIL-8 to evoke dermal inflammation.
Materials and Methods
Cells.
￿
DogPBMC and granulocytes were prepared by density
gradient centrifugation on 1.084 g/ml Percoll as described (19).
THP-1cellswere cultured in IMDM with 10% fetal bovine serum
(GIBCO BRL, Gaithersburg, MD).
RANTES, MIP-1a, MCP-1, and11,8.
￿
Allrecombinant human
chemokines were purchased from Peprotech (Princeton, NJ) and
had <0.1 ng LPS/Wg protein as determined by the Limulus Ame-
bocyte Lysis assay (Whittaker Bioproducts, Walkersville, MD). MIP-
la was iodinated with ChloramineT according to Siciliano et al.
(20) and a sp act of 14 ACi/hg. Bolton-Hunter labeled RANTES
and MCP-1 was purchased from New England Nuclear (Boston,
MA) and each had a sp act of 260 uCi/Pg.
Binding Assays.
￿
Binding of 10,000-20,000 cpm (50-100 pM)
of 1251-ligands in the presence of varying concentrations of unla-
beled ligand to cells at room temperature was assayed in 50 mM
Hepes/1 mM, CaC12/5 mM, and MgC12/0.5% BSA, pH 7.2.
Competition assays were performed by premixinglabeled andcold
ligand and initiating the assay by the addition of cells. Activity
retained on polyethyleneimine-treated filters (Glass fiber size C;
Whatman Laboratory Products, Clifton, NJ) after washing in
bindingbuffer with 0.5 M NaCl wascounted in agamma counter
(LKB Instruments, Gaithersburg, MD). Binding constants were
calculated and Scatchard analyses were performed on competition
binding assays using the LIGAND program (Dr. P. J. Munson,
National Institutes of Health, Bethesda, MD) and are shown as
the mean ± SD.
Intradermal Chemokine Challenge. Conscious 3-yr-old female
beagles, parasite free at. the time ofchallengebut having had some
parasite exposure -2 yr previously, were shaved andthen subjected
to skin challenge by intradermal injection at up to 12 skin sites.
Doses of chemokine ranged from 10 to 500 pmol/site in a vehicle
of PBS containing 0.1% human serum albumin, or with LPS in
vehicle, or with vehicle aloneas controls. At specific times (4-24 h)
afterintradermal injection ofagonist, 6-mm punchbiopsies of skin
sites were obtained under anesthesia (thiamyl 2% to effect and 0.05
mg/kg acepromazine, i.m.), and the 5-Am paraffin-embedded he-
matoxylin and eosin-stained histology was examined. Each dose
of each chemokine was examined in duplicate sites in two dogs
I Abbreviations used in this paper: hMCP-1, human monocyte chemoattrac-
tant protein 1; hMIP-la, humanmacrophage inflammatory protein 1a;
i.d., intradermal.
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in four separate experiments (RANTES), three experiments for
IL-8 and MCP-1, and a single experiment for MIP-1a. Full blood
counts and differentials were performed on EDTA-anticoagulated
bloodby VetResearch (ValleyStream,NY), andadditional differen-
tial peripheral bloodcounts were performedon Diff-Quik (Baxter
Healthcare, Glendale, CA) stained bloodsmears and are expressed
as themean ± SD. NewZealandWhiterabbits (HazeltonSystems,
Aberdeen, MD) and Sprague-Dawley rats (Charles RiverLabora-
tories, Wilmington, MA) were skin challenged under ketamine-
xylazine anesthesia and biopsied after euthanasia. Escherichia coli
0111:134 LPS from Difco Laboratories (Detroit, MI) was used for
injection. All animal experimentation was approved by and under
the supervision of the Institutional Animal Care and Use Com-
mittee.
Quantitation ofDermalInfiltrates.
￿
Five codedserial 5 A.m hema-
toxylin and eosin-stained paraffin sections from each skin site were
examined blind by at least two observers. Dermal infiltration was
measured by counting the absolute numbers of extravascular eo-
sinophils, macrophages, neutrophils, andlymphocytes at amagnifi-
cation of 400 in a counting grid of 16 squares empirically deter-
mined to cover an area 24.5 x 24.5 Am. Dermal infiltrations were
counted in each of three serial sections, from a minimum of four
separate sites from four dogs, andexpressedas thenumbers of each
cell type per mm' ± SEM, rounded to the nearest ten. The
numbers of separate skin site enumerated are shown (see Table 1).
Thetypicallowpower appearance of sites quantified is shown (see
Figs. 2A, 3 C, 4A, and5A). Dermal siteswere specifically chosen
because infiltration of the subdermal fat resulted in dense cords
ofleukocytes, too intense to permit adequate counting anddifferen-
tiation of the leukocyte typesby nuclear andcytoplasmic granular
morphology.
Results and Discussion
The Canine RANTES Receptor Binds Human RANTES
but not hMIP-1a. We previously demonstrated that dog
mononuclear cells bound human RANTES and human
MCP-1, and underwent a ligand-induced Cat+ flux when
exposed to 100 nM RANTES or 10 nM MCP-1 (19). Equi-
librium binding studies on thecanine RANTES receptor on
intact mononuclear cells showed a single receptor with Kd
of 14 ± 8 pM and 830 ± 80 sites/cell (Fig. 1). Receptor
assays were also performed on a mixed population of canine
granulocytic cells, whichdisplayed an identicalbinding con-
stant but a lower site number of -200 sites/cell. A similar
site number of 190 sites/cell was obtained on a mixed popu-
lation of human granulocytes, probably reflecting the small
proportion of eosinophils present. The canine RANTES
receptor has no measureable binding affinity for human
1251-MIP-1a (Fig. 1). In contrast, in our hands, and as
reported by others (21-23), the RANTES/MIP-1a receptor
on human THP-1 membranes, binds both RANTES and
MIP-lca, which compete fully for each other, with Kd on
isolated membranes of 70 ± 20 and 200 ± 20 pM, respec-
tively (data not shown) .
Intradermal Injection of hRANTES in Dog Resulted in Eo-
sinophilic and Monocytic Inflammatory Response. Whereas
human RANTES (500 pmol/site, intradermal [i.d.]) evoked
no dermal response in rat and rabbit (data not shown) de-
spite some specific binding to mononuclear cells (19), in-
tradermal injection in the dog resulted in dose- and time-
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Figure 1.
￿
Equilibrium binding cold displacement by RANTES of 1251-
RANTES to canine PBMC ("). Thepoints represent themeansoftripli-
catemeasurements with a superimposed four-parameter fit. Scatchardanal-
yses showed asingle high affinity receptor for 1251-RANTES with Kd of
14 t 7.8 pM (inset). 1251_MIP-la failed to bind to canine PBMC (0).
Data from one of two similar experiments are shown. Superimposable
equilibrium competition binding was obtained on canine granulocytes.
dependent inflammatory responses in 15 of 16 sites analyzed.
Cell counts of extravascular leukocytes derived from the tissue
histology are summarized in Table 1. Fig. 2 shows the histology
of RANTES- and vehicle alone-injected skin sites. Injection
of as little as 10 pmol/site i.d. resulted in perivascular dermal
cuffing with monocytes and eosinophils at 24 h (Fig. 2 B).
Higher doses of 50 pmoles and 500 pmol/site resulted in
inflammatory lesions of increasing severity, with diffuse, full-
thickness dermal inflammation seen at the highest dose at
24 h (Fig. 2 A). At all dose levels of RANTES, the evoked
responses were characterized by the subcutaneous accumula-
tion of eosinophils, macrophages, and a smaller number of
neutrophils on the periphery of lesions (Table 1, Fig. 3 C) .
The abundant subcutaneous perivascular eosinophilic infiltrate
is shown in Fig. 2 C. The bulk ofcanine eosinophils recruited
to sites ofhRANTES injection have copious intact eosinophilic
granules, and there is little histological evidence ofRANTES-
induced eosinophil degranulation in vivo (Fig. 2 D). Immuno-
logical evidence for extracellular eosinophil major basic pro-
tein couldbe a more sensitive measure of secretory responses.
Dvorak (24) has documented degranulation ofcrystalline major
basic protein-containing cores in vivo by electron micros-
copy without complete loss of granule contents. It should
be noted that RANTES-injected skin sites showed no indu-
ration at 24 h, and no swelling was evident, though some
separation of collagen fibrils could be seen histologically.
TheKinetics ofthe Canine Response to Intradermal hRANTES
Injection. Within 4 h of hRANTES injection, eosinophilic
and monocytic cuffing of dermal and subcutaneous venules
was seen (Fig. 3 A). There was also evidence for intravas-
cular eosinophil activation with adherence of eosinophils to
endothelium'and homotypic aggregation ofeosinophils (Fig.
3 B), despite the presence of apparently intact cytoplasmic
granules in extravascular eosinophils by light microscopy (Fig.
2 D). Intravascular leukocytes were not included in Table 1.
Cell accumulation increased at 8 h and plateaued between
16 and 24 h (Fig. 2 A, Table 1) . Few neutrophils were evi-
dent at the 4-h time point, whereas a significant peripheral
neutrophilic infiltrate (12 ± 1.4% of recruited cells) was seen
at the latertime points, and was probably secondary to mono-
Table 1.
￿
The Numbers and Types of Leukocytes Infiltrating the Canine Dermis at Varying Times after Intradermal Injection
of RANTES, MCP-1, IL-8, or Vehicle
Results reflect cell counts from three serial sections from the minimum of four separate skin sites from four animals. Cell counts (rounded to the
nearest 10) are expressed as the mean ± SEM of cells/mm2.
Treatment Time
Sites
counted PMN Monocytes Eosinophils Lymphocytes
pmol/site h
Vehicle 24 8 0 180 ± 60 20 ± 10 0
RANTES (10) 24 4 80 ± 30 630 ± 100 350 ± 60 30 ± 10
RANTES (50) 24 4 270 ± 60 925 ± 110 780 ± 140 60 ± 20
RANTES (500) 4 4 70 ± 20 550 ± 40 340 ± 50 30 ± 10
RANTES (500) 8 4 190 ± 20 470 ± 30 420 ± 50 60 ± 10
RANTES (500) 16 4 330 ± 40 900 ± 230 750 ± 100 70 ± 20
RANTES (500) 24 8 350 ± 40 1,200 ± 110 1,480 ± 160 140 ± 20
IL-8 (500) 4 4 2,740 ± 280 100 ± 20 90 ± 20 40 ± 10
IL-8 (500) 24 4 1,810 ± 180 170 ± 40 120 ± 30 390 ± 70
MCP-1 (500) 24 4 30 ± 10 610 ± 220 20 ± 10 60 ± 10
MIP-1a (500) 24 4 120 ± 20 320 ± 70 70 ± 40 0Figure 2 .
￿
Hematoxylin- and eosin-stained sections of 24-h dermal responses to RANTES. (A) High dose (500 pmol/site) RANTES challenge resulted
in full-thickness dermal inflammation . x100. (B) Low dose (10 pmol/site) RANTES injection resulted in diffuse perivascular cuffing by monocytes
and eosinophils . x 160. (C) The predominant lesions were eosinophil- and macrophage-rich perivascular infiltrates, with abundant intact eosinophils .
x400. (D) Little histological evidence of release of eosinophil granules into the interstitium can be seen at high power, which show intact eosinophils
with characteristically large cytoplasmic granules . x1,000 . (E) Vehicle-injected control site. x100 .
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￿
Hematoxylin- and eosin-stained sections showing the kinetics of the dermal response to exogenous human RANTES. (A) 4-h RANTES
sites show eosinophilic and monocytic cuffing of small venules (arrows) x250 . (B) Evidence for intravascular activation of eosinophils by RANTES
at 4 h . Vessels show adherent eosinophils and intravascular homotypic eosinophil aggregates adherent to the vessel wall . x 250. (C) Some neutrophil
infiltration is seen in addition to eosinophils and monocytes by 16 h . x250 . (D) At 24 h, monocytes are the major cell type adherent to small vessel
endothelium . x 400 .
cyte and eosinophil recruitment (Fig. 3 C, Table 1) . At 4 h,
the eosinophil was the predominant cell adherent to the post-
capillary venular endothelium, whereas the endothelial ad-
herent leukocytes at 24 h were mainly monocytic (Fig. 3 D) .
The adherent of cells to endothelium visible in tissue sec-
tions is but a static moment in the dynamic formation and
maintenance of an extravascular inflammatory site, and may
not correlate exactly with the numbers and types of leuko-
cytes quantified in Table 1.
Comparison oftheRANTES Response with Equivalent Doses
ofhMCP-1 . To contrast potential differences between the
monocytic and eosinophilic response toRANTES, we simul-
taneously compared its in vivo effects to those of the monocyte-
specific C-C chemokinehMCP-1 . hMCP-1 injection produced
mild perivascular cuffing and dermal infiltration by mono-
cytes at 500 pmol/site (Fig. 4 A, Table 1) . This was at a dose
-50-fold-greater than that needed to elicit a reproducible re-
sponse to RANTES. We have now examined MCP-1 responses
to human chemokines in rat, guinea pig, rabbit, dog, and
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rhesus. In all cases, we only see leukocyte recruitment when
there is both high affinity binding (19) and a ligand-dependent
Cal+ flux (i.e., in dog and rhesus) . Rat cells did not bind
MCP-1 and rabbit cells did not undergo a ligand-dependent
Caz+ flux (19) . Despite published reports to the contrary
(16, 17) in rat and rabbit, we saw no significant responses
to MCP-1 in those species. A similar inability to reproduce
the results upon injection ofhMCP-1 into rat and rabbit have
been alluded to by Yoshimura and Yuhki (25) . The results
obtained in canines are similar to those shown by Yoshimura
in autologous guinea pig MCP-1 cutaneous challenges (26) .
hMCP-1 alone in the canine is a less effective proinflamma-
tory stimulus on a molar basis than RANTES or IL-8 .
As expected from the failure to demonstrate specific binding
of hMIP-1a to canine mononuclear cells, negligible dermal
responses were elicited by up to 500 pmoles/site of this
chemokine .
The Dermal Response to hIL-8 Peaks by 4 h and Persists at
24 h .
￿
hIL-8 evokes an abundant neutrophilic infiltrate that1918
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￿
Hematoxylin- and eosin-stained sections ofhIL8-injected skin sites. (A) hIIr8 induced a pronounced neutrophilic infiltrate at 4 h. x250 .
(B) Some PMN were still detectable at 24 h, though the area ofinfiltrate was somewhat diminished . x 160 . (C) A subpopulation of small lymphocytic
cells could also be seen at 24 h (arrows) .
￿
x400 .
was maximal within 4 h after injection and still persists at
24 h (Fig. 5, A and B, and Table 1) . By 24 h, a distinct sub-
population of small lymphocytic cells in addition to the pre-
dominant neutrophils, can be seen at hIL-8 sites (Fig. 5 C) .
The early peak ofhIL-8 response (4 h) compared to RANTES
(16 h-24 h) could perhaps reflect the kinetics and life spans
of the responding leukocyte subsets, and their relative abun-
dance in the peripheral blood . In these experimental animals,
neutrophils are the most abundant leukocyte, and also mi-
grate the fastest in vitro. Additional possibilities are the different
rates of in vivo metabolism of the two chemokine families,
for which no data currently are available. It has been recently
reported (27) that IL-8 is inactivated by the C5a-inactivating
protease. The difference in kinetics of migration probably does
not reflect any physical difference between the C-X-C and
C-C chemokines such as binding to negatively charged ex-
tracellular matrix, as they are all highly conserved basic pro-
teins, with theoretically superimposible structures (28) . A
third explanation could be that RANTES evokes a series of
indirect effects leading to longer-term recruitment of eo-
sinophils and monocytes, and Ab neutralization studies would
allow indirect effects to be quantified .
TheProinflammatory Activity ofRANTES Is NotLPS Medi-
ated. The proinflammatory activity of hRANTES cannot
be explained by LPS contamination . LPS levels were <100
pg/p,g of protein and these protein preparations were inac-
tive in the same dose range in rabbit and rat, both LPS-
responsive species. Also, injection of 0.4ng ofLPS in vehicle
as a control during these experiments resulted in a very mild
perivascular monocytec infiltrate at 24 h, with some neutro-
phils adherent to the endothelium of small venules, a histo-
logical response very different from that seen with WANTES.
The property of hRANTES to recruit eosinophils and
monocytes to extravascular sites is distinct, and different from
Figure 4 .
￿
Hematoxylin- and eosin-stained sections of the canine dermal response to exogenous hMCP-1 . (A) hMCP-1 at 500 pmol/site induces
a mild perivascular monocytic infiltrate. In contrast to the responses to hRANTES and hIIT8, no evidence of subcutaneous cellular infiltrates could
be seen with hMCP-1 . (B) Vehicle-injected control skin site . A and B, x100 .
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pressed as the mean ± SD for the group of dogs.
the responses elicited by hIL-8and the human C-C chemokine
MCP-1, both ofwhich were injected simultaneously at sepa-
rate sites as controls in each experiment. The cellular com-
position of each inflammatory site reflected the chemokine
injected at the local site, suggesting that chemokines are lo-
cally active. These data are not in keeping with the possi-
bility that chemokines are acting systemically under these
conditions.
Canines have a normal range ofperipheral blood eosinophils
of between 2 and 10%. These dogs were near the upper limit
of the normal range, were helminth free but had some prior
exposure to parasites. The relative abundance of peripheral
blood eosinophils (Table 2) and perhaps eosinophil priming
may have contributed to the florid nature of the RANTES
response in these animals. This possibility couldbest be ana-
References
lyzed in a small animal system, where reproducible priming
could be experimentally obtained, but would require using
either mouse or guinea pig RANTES. In those systems, the
extent ofeosinophil recruitment could perhaps be most quan-
titatively assessed by the use of a biochemical marker for the
presence of eosinophils such as major basic protein.
These data suggest that RANTES couldplay a significant
role in diseases characterized by eosinophilia and the mobili-
zation of eosinophils and monocytes to sites oftissue damage
such as the asthmatic lung (2) and atopic dermatitis (29).
This report provides the first direct evidence in vivo that the
selective migration of leukocyte subsets to C-C chemokines
such as RANTES in vitro, has some correlation in vivo, and
supports the caveat that studies in vivo with exogenous cyto-
kine across a species barrier can be adequately interpreted only
when performed in concert with detailed characterization of
the target receptor and the functional sequelae of receptor
occupancy and activation by the exogenous cytokine.
A critical problem facing the chemokine fieldhas been the
need to demonstrate a relationship in vivo between chemokine
presence, the presence of specific, activatible receptors, and
leukocyte recruitment. This has now been achieved at least
for RANTES and IL-8 (30). Additional approaches including
neutralizing mAbs or chemokine gene deletion by homolo-
gous recombination, together with a detailed understanding
of these ligands and their receptors, should then facilitate our
understanding of the factors regulating leukocyte recruitment
to sites of tissue damage and repair.
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